Evelo Biosciences, Inc. (EVLO)
$1.04
Rating:
Recommendation:
-
| Symbol | EVLO |
|---|---|
| Price | $1.04 |
| Beta | 1.441 |
| Volume Avg. | 0.12M |
| Market Cap | 114.000M |
| Shares () | - |
| 52 Week Range | 0.94-5.285 |
| 1y Target Est | - |
| DCF Unlevered | EVLO DCF -> | |
|---|---|---|
| DCF Levered | EVLO LDCF -> | |
| ROE | -1298.75% | Strong Sell |
| ROA | -138.57% | Strong Sell |
| Operating Margin | - | |
| Debt / Equity | 824.96% | Strong Buy |
| P/E | - | |
| P/B | 12.04 | Strong Buy |
Latest EVLO news
About
Download (Excel)Evelo Biosciences, Inc., a biotechnology company, discovers and develops oral biologics for the treatment of inflammatory diseases and cancer. It is developing EDP1815, a whole-microbe candidate for the treatment of inflammatory diseases; and is in Phase 2 clinical trial for the treatment of psoriasis and atopic dermatitis, as well as for the hyperinflammatory response associated with COVID-19. The company also develops EDP1867, an inactivated investigational oral biologic, which is in Phase 1b for the treatment of inflammatory diseases; EDP2939, an extracellular vesicle investigational oral biologic for the treatment of inflammatory diseases; and EDP1908, a product candidate for oncology. Evelo Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.